MDL 101028

Drug Profile

MDL 101028

Latest Information Update: 01 Sep 1998

Price : $50

At a glance

  • Originator Aventis
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpes simplex virus infections; HIV infections

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
  • 01 Sep 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 01 Feb 1995 A study has been added to the antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top